Zacks Research Expects Stronger Earnings for Aethlon Medical

Aethlon Medical, Inc. (NASDAQ:AEMD) – Zacks Research upped their Q2 2027 earnings per share estimates for shares of Aethlon Medical in a report released on Wednesday, August 19th. Zacks Research analyst M. Marin now expects that the medical equipment provider will post earnings per share of ($2.17) for the quarter, up from their previous estimate of ($4.05). The consensus estimate for Aethlon Medical’s current full-year earnings is ($8.53) per share. Zacks Research also issued estimates for Aethlon Medical’s Q3 2027 earnings at ($2.17) EPS, Q4 2027 earnings at ($2.18) EPS and FY2027 earnings at ($10.55) EPS.

AEMD has been the subject of several other reports. Wall Street Zen raised shares of Aethlon Medical to a “sell” rating in a report on Saturday, August 8th. HC Wainwright reiterated a “neutral” rating and issued a $1.50 price target on shares of Aethlon Medical in a research report on Tuesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $1.50.

Aethlon Medical Stock Performance

NASDAQ:AEMD opened at $2.70 on Friday. The stock has a 50-day simple moving average of $4.26 and a two-hundred day simple moving average of $8.44. Aethlon Medical has a 52-week low of $2.63 and a 52-week high of $137.00. The firm has a market capitalization of $1.92 million, a PE ratio of -0.08 and a beta of 1.41.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.92) by ($0.10).

Institutional Trading of Aethlon Medical

A hedge fund recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent SEC filing. 1.99% of the stock is owned by institutional investors and hedge funds.

More Aethlon Medical News

Here are the key news stories impacting Aethlon Medical this week:

• Positive Sentiment: Zacks Research raised its FY2027 EPS forecast to a loss of $10.55 per share from a projected loss of $16.15, while increasing its Q2, Q3 and Q4 2027 estimates to losses of approximately $2.17–$2.18 per share from $4.05. The revisions suggest analysts expect lower expenses or improved operating performance, though Aethlon remains unprofitable. Zacks Research estimate revisions
• Neutral Sentiment: Aethlon’s oncology study is advancing, while the company continues cost-efficient preclinical work involving other diseases. The update may support the company’s longer-term therapeutic pipeline, but it does not provide a near-term revenue or approval catalyst. AEMD: Oncology Study Advances; Cost-Efficient Preclinical Activities Regarding Other Diseases Continue
• Negative Sentiment: HC Wainwright maintained a Neutral rating and a $1.50 price target, below AEMD’s recent trading level. Its forecasts call for continued losses in FY2027 through FY2030, with EPS estimates of ($0.92), ($0.57), ($0.69) and ($0.22), respectively. This valuation gap and ongoing losses can weigh on investor sentiment. HC Wainwright Predicts Aethlon Medical FY2031 Earnings
• Negative Sentiment: Aethlon’s financial outlook remains highly speculative. The company previously reported a quarterly loss of $4.02 per share, missing the $3.92 consensus estimate, and analysts still expect a full-year loss of approximately $8.53 per share. With the shares far below their 50-day and 200-day moving averages, technical and fundamental factors remain unfavorable.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.